Nitin DamleSenior Vice President and Head, Discovery Biology/ CSO, Sun Pharma Advanced Research Company Limited Sorry, There is currently no biography for this presenter. |
Rajan DigheProfessor, Indian Institute of Science The research activities of the laboratory of Prof. Dighe are combination of basic and translational research. The principal objective of the laboratory is to study the mechanism of receptor activation with emphasis on the glycoprotein hormone-receptor interactions.Recently, the laboratory has also been investigating the mechanism of “Notch” activation.These studies involve a very interesting approach of using polyclonal, monoclonal and recombinant antibodies against both hormones and their receptors to elucidate the molecular details of hormone-receptor interactions and receptor activation. The translational potential of these studies is evident from the observations that the antibodies against glycoprotein hormone receptors can be used to treat conditions such as precocious puberty or infertility caused by either “gain/loss of function” mutations in the receptors. Similarly, it was demonstrated that an antibody specific for the “gain-of-function” of Notch receptor associated with T-ALL can be used treat hematological cancers. The same antibody, in combination with chemotherapeutic drugs, can be used to treat a variety of cancers. Presently, the laboratory is characterizing recombinant antibodies against different domains of Notch with the hope of developing potential cancer immunotherapeutics. The other research interests of the laboratory are development of novel immunization strategies for human and animal vaccines, gene expression during spermatogenesis and biotechnology of gonadotropins. |
Satish SinghHead, Lonza Inc Dr. Satish Singh is Head of Drug Product Process Development, in the Drug Product Services group at Lonza AG. Prior to joining Lonza recently, Satish was Research Fellow and Group Leader at Pfizer’s BioTherapeutics Pharmaceutical R&D unit. Satish has more than 25 years’ experience in the industry in product development activities, and is an internationally recognized expert in all aspects of (bio)pharmaceutical Drug Product (biologics, vaccines and small molecules) development. His experience includes ophthalmics and parenterals, encompassing small molecules and biologics, and has been involved in the submission of several BLAs and INDs. Satish has a strong technical background, complemented by a deep understanding of regulatory challenges and the evolving regulatory landscap. He is involved in various professional groups through the AAPS as well as USP. His research interests also include the investigation of impact of freezing processes on proteins, use of computational approaches to mitigate develop-ability issues, and aggregation and immunogenicity. He obtained his B.Tech. from the Indian Institute of Technology, New Delhi, and an M.S. and Ph.D. in Chemical Engineering from Kansas State University. He holds the position of Adjunct Professor at the Dept. of Physical Pharmaceutical Chemistry at Uppsala University, Sweden. |
Dimiter Stanchev DimitrovProfessor, University of Pittsburgh Dr. Dimitrov graduated and completed his PhD at the University of Sofia, Sofia, Bulgaria, and thereafter he worked in the Bulgarian Academy of Sciences where he defended his ScD and was Professor of Biophysics until he joined the National Cancer Institute (NCI) of the National Institutes of Health (NIH), USA, in 1990. There he was tenured as Senior Investigator and appointed at the Senior Biomedical Research Service. He left for the University of Pittsburgh in 2017 to start a Center for Antibody Therapeutics. He is expert in display/screening/libraries methodologies, antibody engineering, and protein biochemistry as well as in mathematical modeling, immunology, virology, physical chemistry and biophysics. His major long-term goal is the development of clinically useful therapeutics and vaccines based on human monoclonal antibodies in different formats including engineered antibody domains, chimeric antigen receptors, bispecific antibodies and antibody drug conjugates. He has authored or coauthored more than 370 articles cited more than 20,000 times, several books and is inventor or coinventor of more than 100 inventions, patent applications or patents. |
